|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Thrombopoietin receptor agonists (TPO-RAs), eltrombopag and romiplostim, increases the platelet production, and are being increasingly used in various conditions with thrombocytopenia.
|
31830528 |
2020 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
|
30646404 |
2019 |
|
Thrombocytopenia
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis.
|
29958825 |
2019 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Described also is a comparative summary of the different aspects of five currently available therapies targeting TPO-R or SYK for the treatment of thrombocytopenia.
|
31226783 |
2019 |
|
Thrombocytopenia
|
0.400 |
CausalMutation
|
phenotype |
CLINVAR |
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.
|
31064749 |
2019 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The thrombopoietin receptor agonist romiplostim improves exposure to chemotherapy in patients with glioblastoma experiencing temozolomide-induced thrombocytopenia.
|
31586022 |
2019 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
|
31055790 |
2019 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
CIT was identified based on: diagnosis code for thrombocytopenia or bleeding; procedure code for platelet transfusion or bleeding control; or drug code for thrombopoietin-receptor agonist.
|
30764783 |
2019 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
|
31152794 |
2019 |
|
Thrombocytopenia
|
0.400 |
GeneticVariation
|
phenotype |
CLINVAR |
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.
|
31064749 |
2019 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Thrombopoietin Receptor Agonists: Can These Be the Future Answer to the Deadly Thrombocytopenia in Dengue Fever?
|
31192066 |
2019 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Lusutrombopag (Mulpleta<sup>®</sup>), an orally bioavailable, small molecule thrombopoietin receptor agonist, is approved for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
|
31529283 |
2019 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation.
|
29956377 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Avatrombopag, an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist, is currently in clinical development for the potential treatment of severe thrombocytopenia in patients with chronic liver disease undergoing an elective procedure.
|
28339166 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
ELT is an agonist at Thrombopoietin receptor, used in treatment of thrombocytopenia.
|
30507954 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Taken together, our findings indicate that, given its favourable pharmacological characteristics, hetrombopag may represent a new, orally active, small-molecule TPOR agonist for patients with thrombocytopenia.
|
30156363 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Lusutrombopag (S-888711), an oral small-molecule thrombopoietin receptor (TPOR) agonist, has gained first approval as a drug to treat thrombocytopenia of chronic liver disease in patients undergoing elective invasive procedures in Japan.
|
29274361 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Preliminary clinical evidence suggests that thrombopoietin receptor agonists (TPO-RAs) with an established use in the treatment of certain acquired thrombocytopenias are well tolerated and provide clinical benefits in patients with some forms of HTP.
|
29956472 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Avatrombopag is an oral thrombopoietin receptor agonist that has been recently approved for treating thrombocytopenia in chronic liver disease patients needing invasive procedures.
|
30203841 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The clinical course suggests that 2 factors, including overproduction of interleukin 6 and autoimmune-mediated thrombocytopenia via thrombopoietin receptor, may have contributed to the pathogenesis of TAFRO syndrome in this patient.
|
29626596 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In this study (ASPIRE), we aimed to assess eltrombopag, an oral thrombopoietin receptor agonist, for thrombocytopenia (grade 4) treatment in adult patients with advanced MDS or AML.
|
29241762 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We tested whether eltrombopag, a thrombopoietin receptor agonist, might be effective in improving thrombocytopenia in lower-risk myelodysplastic syndromes and severe thrombocytopenia.
|
28162984 |
2017 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In rare cases in which thrombocytopenia is the main clinical problem leading to clinically significant bleeding events, thrombopoietin receptor analogues may alleviate bleeding, increase platelet counts, and rarely lead to trilineage responses.
|
29222293 |
2017 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Thrombopoietin receptor agonists were given to 10 patients but did not shorten the duration of thrombocytopenia, reduce severe bleeding, or early death.
|
28910610 |
2017 |
|
Thrombocytopenia
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage.
|
27885890 |
2017 |